首页> 外文期刊>Cancer causes and control: CCC >Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study.
【24h】

Infertility, treatment of infertility, and the risk of breast cancer among women with BRCA1 and BRCA2 mutations: a case-control study.

机译:患有BRCA1和BRCA2突变的女性的不育症,不育症治疗和患乳腺癌的风险:一项病例对照研究。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: Women with a breast cancer susceptibility gene 1 (BRCA1) or breast cancer susceptibility gene 2 (BRCA2) mutation are at increased risk for developing breast and ovarian cancer. Various reproductive and hormonal factors have been shown to modify the risk of breast cancer. These studies suggest that estrogen exposure and deprivation are important in the etiology of hereditary cancer. Many patients are interested in the possibility of an adverse effect of fertility treatment on breast cancer risk. It is important to evaluate whether or not infertility per se or exposure to fertility medications increase the risk of breast cancer in genetically predisposed women. METHODS: We conducted a matched case-control study of 1,380 pairs of women with a BRCA1 or BRCA2 mutation to determine if a history of infertility, the use of fertility medications, or undergoing in vitro fertilization (IVF) were associated with and increased the risk of breast cancer. RESULTS: Sixteen percent of the study subjects reported having experienced a fertility problem and 4% had used a fertility medication. Women who had used a fertility medication were not at significantly increased risk of breast cancer (odds ratio [OR] = 1.21; 95% confidence interval [CI] = 0.81-1.82) compared to non-users. Furthermore, there was no risk associated with a history of use of a fertility medication when the subjects were stratified by parity: (OR = 1.29; 95% CI = 0.83-2.01 for nulliparous women and OR = 0.81; 95% CI = 0.30-2.22 for parous women). CONCLUSIONS: The results of this study suggest that the use of fertility medications does not adversely affect the risk of breast cancer among BRCA mutation carriers. Given the small sizes of the exposed subgroups, these findings should be interpreted with caution and confirmatory studies are required.
机译:背景:具有乳腺癌易感基因1(BRCA1)或乳腺癌易感基因2(BRCA2)突变的女性患乳腺癌和卵巢癌的风险增加。各种生殖和激素因素已被证明可以改变患乳腺癌的风险。这些研究表明,雌激素暴露和剥夺在遗传性癌症的病因中很重要。许多患者对生育治疗对乳腺癌风险的不利影响感兴趣。重要的是评估不育本身或接触生育药物是否会增加遗传易感女性的乳腺癌风险。方法:我们对1,380对具有BRCA1或BRCA2突变的妇女进行了配对病例对照研究,以确定是否有不育史,是否使用生育药物或进行体外受精(IVF)是否与之相关并增加了患病风险乳腺癌。结果:16%的研究对象报告遇到了生育问题,4%的人使用了生育药物。与未使用避孕药的妇女相比,使用过生育药的妇女患乳腺癌的风险没有显着增加(几率[OR] = 1.21; 95%置信区间[CI] = 0.81-1.82)。此外,按受检者分层时,没有与使用生育药史相关的风险:(OR = 1.29;未生育妇女的95%CI = 0.83-2.01; OR = 0.81; 95%CI = 0.30-对于同性女性为2.22)。结论:本研究结果表明,使用生育药不会对BRCA突变携带者中的乳腺癌风险产生不利影响。鉴于暴露亚组的规模较小,应谨慎解释这些发现,并需要进行验证性研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号